<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.8.3">Jekyll</generator><link href="http://www.combattb.org/feed.xml" rel="self" type="application/atom+xml" /><link href="http://www.combattb.org/" rel="alternate" type="text/html" /><updated>2018-07-24T07:36:43-05:00</updated><id>http://www.combattb.org/</id><title type="html">combatTB</title><subtitle></subtitle><entry><title type="html">New findings on drug-resistant TB in Ethiopia</title><link href="http://www.combattb.org/ethiopia_drtb/" rel="alternate" type="text/html" title="New findings on drug-resistant TB in Ethiopia" /><published>2018-06-03T19:49:37-05:00</published><updated>2018-06-03T19:49:37-05:00</updated><id>http://www.combattb.org/ethiopia_drtb</id><content type="html" xml:base="http://www.combattb.org/ethiopia_drtb/">### Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia

Multidrug drug-resistant tuberculosis (MDR-TB) is a major health problem and seriously threatens TB control and prevention efforts globally. Ethiopia is among the 30th highest TB burden countries for MDR-TB with 14% prevalence among previously treated cases. The focus of this study was on determining drug resistance patterns of Mycobacterium tuberculosis among MDR-TB suspected cases and associated risk factors.

A [new paper](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197737) by Mesfin et al in [PLOS One](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197737) reports on
a GeneXpert MTB/RIF based study of patients infected with drug resistant TB.</content><author><name></name></author><summary type="html">Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia</summary></entry><entry><title type="html">Test holds promise to discreminate latent from active TB</title><link href="http://www.combattb.org/discriminating_latent_active_tb/" rel="alternate" type="text/html" title="Test holds promise to discreminate latent from active TB" /><published>2018-05-31T19:49:37-05:00</published><updated>2018-05-31T19:49:37-05:00</updated><id>http://www.combattb.org/discriminating_latent_active_tb</id><content type="html" xml:base="http://www.combattb.org/discriminating_latent_active_tb/">### Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis

Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish between latent infection and active tuberculosis is one of the major limits of currently available diagnostic tools.

A [new study](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197825) by Bella et al in [PLOS One](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197825) evaluates the
LIOSpot® TB anti-human IL-2 ELISpot assay for distinguishing between latent and active TB infection.</content><author><name></name></author><summary type="html">Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis</summary></entry><entry><title type="html">Tuberculosis: Pharmacists develop new substance to counteract antimicrobial resistance</title><link href="http://www.combattb.org/new_amr/" rel="alternate" type="text/html" title="Tuberculosis: Pharmacists develop new substance to counteract antimicrobial resistance" /><published>2018-05-23T19:49:37-05:00</published><updated>2018-05-23T19:49:37-05:00</updated><id>http://www.combattb.org/new_amr</id><content type="html" xml:base="http://www.combattb.org/new_amr/">Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.</content><author><name></name></author><summary type="html">Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.</summary></entry><entry><title type="html">Phylogeny image</title><link href="http://www.combattb.org/c3/" rel="alternate" type="text/html" title="Phylogeny image" /><published>2015-10-09T19:49:37-05:00</published><updated>2015-10-09T19:49:37-05:00</updated><id>http://www.combattb.org/c3</id><content type="html" xml:base="http://www.combattb.org/c3/">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.


Facile est hoc cernere in primis puerorum aetatulis. Longum est enim ad omnia respondere, quae a te dicta sunt. Aliud igitur esse censet gaudere, aliud non dolere. Nam si amitti vita beata potest, beata esse non potest. Facillimum id quidem est, inquam.

Nummus in Croesi divitiis obscuratur, pars est tamen divitiarum. Quid igitur, inquit, eos responsuros putas? Sed ne, dum huic obsequor, vobis molestus sim. An hoc usque quaque, aliter in vita? Negat enim summo bono afferre incrementum diem. Quid autem habent admirationis, cum prope accesseris? Quare attende, quaeso.

Nam, ut sint illa vendibiliora, haec uberiora certe sunt. Minime vero istorum quidem, inquit. Ex ea difficultate illae fallaciloquae, ut ait Accius, malitiae natae sunt. Quamquam id quidem, infinitum est in hac urbe;

Multoque hoc melius nos veriusque quam Stoici. Illi enim inter se dissentiunt. Tubulum fuisse, qua illum, cuius is condemnatus est rogatione, P. Id et fieri posse et saepe esse factum et ad voluptates percipiendas maxime pertinere. Ut proverbia non nulla veriora sint quam vestra dogmata. Atqui eorum nihil est eius generis, ut sit in fine atque extrerno bonorum.</content><author><name></name></author><summary type="html">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.</summary></entry><entry><title type="html">Screenshot of Galaxy analysis page</title><link href="http://www.combattb.org/c2/" rel="alternate" type="text/html" title="Screenshot of Galaxy analysis page" /><published>2015-10-09T19:49:37-05:00</published><updated>2015-10-09T19:49:37-05:00</updated><id>http://www.combattb.org/c2</id><content type="html" xml:base="http://www.combattb.org/c2/">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.


Facile est hoc cernere in primis puerorum aetatulis. Longum est enim ad omnia respondere, quae a te dicta sunt. Aliud igitur esse censet gaudere, aliud non dolere. Nam si amitti vita beata potest, beata esse non potest. Facillimum id quidem est, inquam.

Nummus in Croesi divitiis obscuratur, pars est tamen divitiarum. Quid igitur, inquit, eos responsuros putas? Sed ne, dum huic obsequor, vobis molestus sim. An hoc usque quaque, aliter in vita? Negat enim summo bono afferre incrementum diem. Quid autem habent admirationis, cum prope accesseris? Quare attende, quaeso.

Nam, ut sint illa vendibiliora, haec uberiora certe sunt. Minime vero istorum quidem, inquit. Ex ea difficultate illae fallaciloquae, ut ait Accius, malitiae natae sunt. Quamquam id quidem, infinitum est in hac urbe;

Multoque hoc melius nos veriusque quam Stoici. Illi enim inter se dissentiunt. Tubulum fuisse, qua illum, cuius is condemnatus est rogatione, P. Id et fieri posse et saepe esse factum et ad voluptates percipiendas maxime pertinere. Ut proverbia non nulla veriora sint quam vestra dogmata. Atqui eorum nihil est eius generis, ut sit in fine atque extrerno bonorum.</content><author><name></name></author><summary type="html">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.</summary></entry><entry><title type="html">Screenshot of COMBAT TB Explorer with JBrowse genome browser</title><link href="http://www.combattb.org/c1/" rel="alternate" type="text/html" title="Screenshot of COMBAT TB Explorer with JBrowse genome browser" /><published>2015-10-09T19:49:37-05:00</published><updated>2015-10-09T19:49:37-05:00</updated><id>http://www.combattb.org/c1</id><content type="html" xml:base="http://www.combattb.org/c1/">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.


Facile est hoc cernere in primis puerorum aetatulis. Longum est enim ad omnia respondere, quae a te dicta sunt. Aliud igitur esse censet gaudere, aliud non dolere. Nam si amitti vita beata potest, beata esse non potest. Facillimum id quidem est, inquam.

Nummus in Croesi divitiis obscuratur, pars est tamen divitiarum. Quid igitur, inquit, eos responsuros putas? Sed ne, dum huic obsequor, vobis molestus sim. An hoc usque quaque, aliter in vita? Negat enim summo bono afferre incrementum diem. Quid autem habent admirationis, cum prope accesseris? Quare attende, quaeso.

Nam, ut sint illa vendibiliora, haec uberiora certe sunt. Minime vero istorum quidem, inquit. Ex ea difficultate illae fallaciloquae, ut ait Accius, malitiae natae sunt. Quamquam id quidem, infinitum est in hac urbe;

Multoque hoc melius nos veriusque quam Stoici. Illi enim inter se dissentiunt. Tubulum fuisse, qua illum, cuius is condemnatus est rogatione, P. Id et fieri posse et saepe esse factum et ad voluptates percipiendas maxime pertinere. Ut proverbia non nulla veriora sint quam vestra dogmata. Atqui eorum nihil est eius generis, ut sit in fine atque extrerno bonorum.</content><author><name></name></author><summary type="html">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quae cum dixisset paulumque institisset, Quid est? Immo videri fortasse. Quid iudicant sensus? Duo Reges: constructio interrete. A quibus propter discendi cupiditatem videmus ultimas terras esse peragratas. Non est ista, inquam, Piso, magna dissensio.</summary></entry></feed>